Neurizon makes appointments to executive team
Ella Day | April 24, 2025 | Appointment | Recruitment, Senior Management | Neurizon, Neurology, als, biotech, neurodegenerative diseases
Neurizon Therapeutics, a clinical-stage biotech company focusing on treatments for neurodegenerative diseases, has announced three leadership appointments. These will support the company’s ambition to commercialise its leading therapy NUZ-001, a treatment for Amyotrophic lateral sclerosis (ALS) motor neurone disease.
Kathryn Williams joins as chief regulatory officer (CRO). She brings over two decades of global regulatory experience, with success in major jurisdictions including the US Food and Drug Administration (FDA) and EU European Medicines Agency (EMA). She will lead Neurizon’s regulatory strategy, with a key focus on advancing NUZ-00 into the HEALEY ALS Platform Trial.
Dr Jeffrey M. Brown has been appointed as chief scientific advisor (CSA). He adds rich scientific knowledge in neuropsychiatric and neurodegenerative disease pathways, having held leadership roles in global biopharma companies including Amgen, Pfizer, Bristol Myers Squibb, Wave and Voyager.
Dr Chris Freitag, who has overseen Neurizon’s clinical studies to date, steps into the role of chief medical advisor (CMA). With nearly 30 years of medical and pharma experience, he focused on oncology and rare diseases and has experience as chief medical officer (CMO) in various biotech companies. Freitag will now guide NUZ-001 through regulatory interactions and prepare for broader market access.
CEO Dr Michael Thurn commented that the appointments, ”bring exceptional experience, business and commercial acumen, and a shared commitment to advancing therapies.”
He added, “We are not only poised to advance NUZ-001 but also to expand our pipeline and deliver impactful outcomes for patients with neurodegenerative diseases and for our shareholders.”
Ella Day
23/4/25
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
